The Procter & Gamble Company PG
Composite 55/100; the shares have moved about 21% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 38/100 — a moderate mark against it.
Quality ranks 74/100 — a moderate point in its favour. Income ranks 71/100 — a moderate point in its favour. Balance-sheet strength ranks 62/100 — a moderate point in its favour.
Valuation ranks 38/100 — a moderate mark against it. Momentum ranks 44/100 — a slight mark against it. Growth ranks 44/100 — a slight mark against it.
What the company does P&G is a global leader in branded consumer staples across five segments: Beauty, Grooming, Health Care, Fabric & Home Care, and Baby/Feminine & Family Care. Its portfolio includes well-known brands such as Tide, Gillette, Pampers, and Olay.
Key financials P&G reports strong profitability with ROE 31.1%, ROA 10.9%, and ROCE 24.2%. Margins are robust: gross 51.0%, operating 23.1%, and net 19.2%. Revenue and EPS growth are 7.4% and 5.8%, respectively. The dividend yield is 2.9% with a payout ratio of 64.3%.
Stock health The stock shows moderate momentum with a 3-month gain of 3.97%, but is down -1.93% over six months. RSI(14) is 52.60, indicating neutral technical momentum. Sideravia scores highlight strong quality (70.5) and income (80.4), but growth (36.0) lags.
Price vs fair value P&G trades at a discount of 8.60% versus the analyst mean target of 160.70. - Recent $3.8B acquisition of Thorne expands its Health Care segment (Simply Wall St., WWD, Quartz, Investing.com). - Forward P/E of 20.92 and PEG of 9.30 suggest fair valuation relative to growth (Sideravia). - High profitability metrics (ROE 31.1%, net margin 19.2%) support the discount (Sideravia).
Looking forward P&G’s focus on premium brands and health care expansion may drive long-term growth. However, growth scores remain subdued, and valuation metrics suggest limited upside near-term. Monitor segment performance, especially in Health Care and Beauty.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.